Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 October 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 190 pages)

 

Export 12 results:
Author Title [ Type(Desc)] Year
Filters: Author is Holden, S. E.  [Clear All Filters]
Journal Article
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study, Diabetes Obes Metab, vol. 16, pp. 957-62, 2014.
S. E. Holden, Jenkins-Jones, S., and Currie, C. J., Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study, PLoS One, vol. 11, p. e0153594, 2016.
C. A. Bannister, Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., and Currie, C. J., Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls, Diabetes Obes Metab, vol. 16, pp. 1165-73, 2014.
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality, Diabetes Obes Metab, vol. 16, pp. 977-83, 2014.
T. Holbrook, Tang, Y., Das, R., Shankar, R. R., Tunceli, K., Williams, J., Radican, L., Holden, S. E., Morgan, C. L., Piercy, J., and Currie, C. J., Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study, Int J Clin Pract, vol. 71, 2017.
S. E. Holden, Jenkins-Jones, S., Morgan, C. L., Schernthaner, G., and Currie, C. J., Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer, Diabetes Obes Metab, vol. 17, pp. 350-62, 2015.
S. E. Holden, Morgan, C. L., Qiao, Q., Jenkins-Jones, S., Berni, E. R., and Currie, C. J., Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study, Diabetes Obes Metab, vol. 19, pp. 1097-1105, 2017.
S. E. Holden, Gale, E. A., Jenkins-Jones, S., and Currie, C. J., How many people inject insulin? UK estimates from 1991 to 2010, Diabetes Obes Metab, vol. 16, pp. 553-9, 2014.
C. J. Currie, Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Voss, B., Rajpathak, S. N., Alemayehu, B., Peters, J. R., and Engel, S. S., Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival, Diabetes Obes Metab, vol. 20, pp. 821-830, 2018.
S. Jenkins-Jones, Parviainen, L., Porter, J., Withe, M., Whitaker, M. J., Holden, S. E., Morgan, C. L., Currie, C. J., and Ross, R. J. M., Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia, Eur J Endocrinol, vol. 178, pp. 309-320, 2018.
S. E. Holden, Jenkins-Jones, S., Poole, C. D., Morgan, C. L., Coghill, D., and Currie, C. J., The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010), Child Adolesc Psychiatry Ment Health, vol. 7, p. 34, 2013.
S. E. Holden, Jenkins-Jones, S., Morgan, C. L., Peters, J. R., Schernthaner, G., and Currie, C. J., Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013, Diabet Med, vol. 34, pp. 770-780, 2017.
[Page last reviewed 4 October 2019]